Similar articles

• Efficacy and safety of sorafenib in combination with mammalian target of rapamycin inhibitors for recurrent hepatocellular carcinoma after liver transplantation.

  Gomez-Martin C, Bustamante J, Castroagudin JF, Salcedo M, Garralda E, Testillano M, Herrero I, Matilla A, Sangro B. Gomez-Martin C, et al. Liver Transpl. 2012 Jan;18(1):45-52. doi: 10.1002/lt.22434. Liver Transpl. 2012. PMID: 21932373 Clinical Trial.
• Personalized molecular targeted therapy in advanced, recurrent hepatocellular carcinoma after liver transplantation: a proof of principle.

  Bhoori S, Toffanin S, Sposito C, Germini A, Pellegrinelli A, Lampis A, Mazzaferro V. Bhoori S, et al. J Hepatol. 2010 May;52(5):771-5. doi: 10.1016/j.jhep.2010.01.025. Epub 2010 Mar 4. J Hepatol. 2010. PMID: 20347502
• Survival of patients with advanced hepatocellular carcinoma: sorafenib versus other treatments.

  Kim HY, Park JW, Nam BH, Kim HK, Choi JI, Kim TH, Kim HB, Kim CM. Kim HY, et al. J Gastroenterol Hepatol. 2011 Nov;26(11):1612-8. doi: 10.1111/j.1440-1746.2011.06751.x. J Gastroenterol Hepatol. 2011. PMID: 21517968
• [The treatment of hepatocellular carcinoma. New developments].

  Kuiken SD, van Delden OM, Richel DJ, Jansen PL. Kuiken SD, et al. Ned Tijdschr Geneeskd. 2009 Apr 4;153(14):668-72. Ned Tijdschr Geneeskd. 2009. PMID: 19425326 Review. Dutch. No abstract available.
• Epidemiology, screening, diagnosis and treatment of hepatocellular carcinoma.

  Hussain K, El-Serag HB. Hussain K, et al. Minerva Gastroenterol Dietol. 2009 Jun;55(2):123-38. Minerva Gastroenterol Dietol. 2009. PMID: 19305372 Review.